Capsugel plans to up micronisation capacity at Quakertown, Pennsylvania facility to provide API processing services for clinical candidates and commercial drugs.
Rumoured IPO-ready Capsugel has added micro-dose capabilities at its facility in Ploërmel, France citing its acquisition of Xcelience as the driver for the expansion.
Germany's MG technologies has agreed to sell the bulk of its
Dynamit Nobel chemicals division, sealing the fate of a company
that has been on the block since last November, writes Phil
Taylor.
